Viva Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 11 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 157.00 Cr
as on 16-11-2024
- Revenue 1526.59%
(FY 2023)
- Profit -460.03%
(FY 2023)
- Ebitda 1634.91%
(FY 2023)
- Net Worth -1224.61%
(FY 2023)
- Total Assets -75.36%
(FY 2023)
About Viva Lifesciences
The Company is engaged in the Infrastructure And Utilities Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹157.00 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Sunilkumar Gupta and Brijesh Soni serve as directors at the Company.
- CIN/LLPIN
U24100MH2013PTC245226
- Company No.
245226
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jul 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Viva Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunilkumar Gupta  | Director | 30-Mar-2015 | Current |
| Brijesh Soni | Director | 30-Mar-2015 | Current |
Financial Performance and Corporate Structure Insights of Viva Lifesciences.
Viva Lifesciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 1526.59% increase. The company also saw a substantial fall in profitability, with a 460.03% decrease in profit. The company's net worth observed a substantial decline by a decrease of 1224.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Viva Lifesciences?
In 2023, Viva Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Laxmi Natural Products Private LimitedActive 26 years 5 monthsSunilkumar Gupta and Brijesh Soni are mutual person
Cellbion Lifesciences Private LimitedActive 17 years 8 monthsSunilkumar Gupta and Brijesh Soni are mutual person
- Sherry Securities Private LimitedActive 29 years 8 months
Sunilkumar Gupta and Brijesh Soni are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 22 May 2020 | ₹157.00 Cr | Satisfied |
How Many Employees Work at Viva Lifesciences?
Unlock and access historical data on people associated with Viva Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Viva Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Viva Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
